Zivo Bioscience Overview
Latest ROE for Zivo Bioscience: 193.68% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow193.68%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Zivo Bioscience's return on equity stands at 193.68%. That is above the Consumer Discretionary sector average of 23.6%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Zivo Bioscience sits higher the Consumer Discretionary benchmark (23.6%) with a ROE of 193.68%. That is roughly 720.8% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A ROE of 193.68% for Zivo Bioscience means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how Zivo Bioscience's ROE evolved across reporting periods, while the comparison chart places ZIVO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Consumer Discretionary, ROE is commonly used to spot outliers. Zivo Bioscience's reading of 193.68% (sector avg 23.6%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.
